Genmab A/S Share Price
Equities
GMAB
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,657.00 DKK | -1.98% |
|
-3.24% | -18.25% |
| 18/05 | Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts | MT |
| 12/05 | Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target | FW |
| Capitalization | 10TCr 1.58TCr 1.36TCr 1.25TCr 1.18TCr 2.17TCr 1,52800Cr 2.23TCr 15TCr 5.79TCr 72TCr 5.92TCr 5.8TCr 2,51200Cr | P/E ratio 2026 * |
22.5x | P/E ratio 2027 * | 15.3x |
|---|---|---|---|---|---|
| Enterprise value | 12TCr 1.88TCr 1.62TCr 1.49TCr 1.4TCr 2.59TCr 1,82100Cr 2.65TCr 18TCr 6.9TCr 86TCr 7.06TCr 6.91TCr 2,99300Cr | EV / Sales 2026 * |
4.4x | EV / Sales 2027 * | 3.53x |
| Free-Float |
95.43% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -1.98% | ||
| 1 week | -3.24% | ||
| Current month | -1.95% | ||
| 1 month | -8.15% | ||
| 3 months | -7.51% | ||
| 6 months | -16.27% | ||
| Current year | -18.25% |
| 1 week | 1,639.5 |  | 1,706 |
| 1 month | 1,546 | | 1,795.5 |
| Current year | 1,546 | | 2,257 |
| 1 year | 1,275 | | 2,257 |
| 3 years | 1,157 | | 2,939 |
| 5 years | 1,157 | | 3,327 |
| 10 years | 786.2 | | 3,327 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +4.49% | 0.75% | 27 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.98% | -3.24% | +25.53% | -41.28% | 1.62TCr | |
| +1.39% | -1.89% | +35.11% | +77.37% | 4.89TCr | |
| -0.25% | -7.74% | +66.73% | +51.47% | 4.53TCr | |
| +0.24% | -7.41% | +58.24% | +451.95% | 2.32TCr | |
| -1.19% | -6.27% | -10.24% | -17.56% | 2.25TCr | |
| -2.12% | -3.90% | +34.74% | -26.96% | 1.74TCr | |
| -1.24% | -12.02% | +35.92% | +195.90% | 1.34TCr | |
| -1.06% | -16.36% | -33.99% | +843.45% | 1.24TCr | |
| -0.28% | -5.39% | +27.38% | - | 1.26TCr | |
| -2.35% | -1.60% | +8.91% | +145.93% | 1.25TCr | |
| Average | -0.77% | -5.60% | +24.83% | +186.70% | 2.24TCr | |
| Weighted average by Cap. | -0.35% | -4.98% | +32.95% | +141.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.75TCr 426.98Cr 368.27Cr 337.35Cr 318.78Cr 587.68Cr 41TCr 602.47Cr 4.02TCr 1.57TCr 19TCr 1.6TCr 1.57TCr 68TCr | 3.24TCr 502.65Cr 433.53Cr 397.13Cr 375.26Cr 691.82Cr 49TCr 709.23Cr 4.73TCr 1.84TCr 23TCr 1.89TCr 1.85TCr 80TCr |
| Net income | 462.48Cr 72Cr 62Cr 57Cr 54Cr 99Cr 6.95TCr 101.26Cr 675.71Cr 263.14Cr 3.27TCr 269.3Cr 263.56Cr 11TCr | 703.55Cr 109.17Cr 94Cr 86Cr 82Cr 150.26Cr 11TCr 154.04Cr 1.03TCr 400.3Cr 4.98TCr 409.68Cr 400.95Cr 17TCr |
| Net Debt | 1.95TCr 301.94Cr 260.42Cr 238.56Cr 225.42Cr 415.57Cr 29TCr 426.03Cr 2.84TCr 1.11TCr 14TCr 1.13TCr 1.11TCr 48TCr | 1.25TCr 193.29Cr 166.71Cr 152.71Cr 144.3Cr 266.03Cr 19TCr 272.73Cr 1.82TCr 708.72Cr 8.81TCr 725.32Cr 709.86Cr 31TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | 1,657.00 kr | -1.98% | 1,49,115 |
| 18/26/18 | 1,690.50 kr | +0.39% | 1,92,636 |
| 13/26/13 | 1,684.00 kr | -1.66% | 1,50,567 |
| 12/26/12 | 1,712.50 kr | +3.22% | 1,76,191 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition